Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer

Journal of Cancer Research and Clinical Oncology

Volumn 129, Issue 11, 2003, Pages 651-654

  Escobar, Pedro F ^a   Markman, Maurie ^a   Zanotti, Kristine ^a   Webster, Kenneth ^a   Belinson, Jerome ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Chemotherapy; Endometrial cancer; Pegylated liposomal doxorubicin

Indexed keywords

CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; DOXORUBICIN DERIVATIVE; FAMOTIDINE; HORMONE; PACLITAXEL; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DRUG EFFECT; DRUG EFFICACY; DRUG TOXICITY; ENDOMETRIUM CANCER; FEMALE; HAND FOOT SYNDROME; HEART DISEASE; HEART EJECTION FRACTION; HOSPITALIZATION; HUMAN; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; STOMATITIS;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; CA-125 ANTIGEN; DOXORUBICIN; DRUG EVALUATION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; LIPOSOMES; MIDDLE AGED; POLYETHYLENE GLYCOLS;

EID: 0345305763     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-003-0497-8     Document Type: Article

References (11)

1. Ball HG, Blessing JA, Lentz SS, Mutch DG (1996) A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 62:278-281
2. Campos SM, Penson RT, Mays AR, Berkowitz RS, Fuller AF, Goodman A, Matulonis UA, Muzikansky A, Seiden MV (2001) The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol 81:206-212
3. Duk JM, Aalders JG, Fleuren GJ, de Bruijn HWA (1986) CA 125: A useful marker in endometrial carcinoma. Am J Obstet Gynecol 155:1097-1102
4. 2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 78:369-372
5. Moore TD, Phillips PH, Nerenstone SR, Cheson BD (1991) Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions. J Clin Oncol 9:1071-1088
6. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang L-J (1997) Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987-993
7. Muggia FM, Blessing JA, Sorosky J, Reid GC (2002) Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 20:2360-2364
8. Rose PG (1996) Endometrial carcinoma. N Engl J Med 335:640-649
9. Rose PG, Maxson JH, Fusco N, Mossbruger K, Rodriguez M (2001) Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol 82:323-328
10. Thigpen T, Blessing J, Homesley H, Malfetano J, DiSaia P, Yordan E (1993) Phase III trial of doxorubicin +/-cisplatin in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group (GOG) study. Proc Am Soc Clin Oncol 12:261
11. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E, Muggia FM, Gabizon A (1995) Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 13:1777-1785